Current Perspectives on the Recognition and Prevention of Dengue Fever Worldwide: Novel Opportunities to Reduce Burden of Disease in 2022

References Toolkit

Resource	Address
Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504-507. doi:10.1038/nature12060	https://www.nature.com/articles/nature12060
Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. *N Engl J Med*. 2019;381(21):2009-2019. doi:10.1056/NEJMoa1903869	https://www.nejm.org/doi/full/10.1056/NEJMoa1903869
Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet*. 2014;384(9951):1358-1365. doi:10.1016/S0140-6736(14)61060-6	https://pubmed.ncbi.nlm.nih.gov/25018116/
Coronel-Ruiz C, Gutiérrez-Barbosa H, Medina-Moreno S, et al. Humanized mice in dengue research: A comparison with other mouse models. *Vaccines (Basel)*: 2020;8(1):39. doi:10.3390/vaccines8010039	https://pubmed.ncbi.nlm.nih.gov/31979145/
Grande AJ, Reid H, Thomas E, Foster C, Darton TC. Tourniquet test for dengue diagnosis: Systematic review and meta-analysis of diagnostic test accuracy. *PLoS Negl Trop Dis*. 2016;10(8):e0004888. doi:10.1371/journal.pntd.0004888	https://pubmed.ncbi.nlm.nih.gov/27486661/
Guy B, Jackson N. Dengue vaccine: Hypotheses to understand CYD-TDV-induced protection. *Nat Rev Microbiol*. 2016;14(1):45-54. doi:10.1038/nrmicro.2015.2	https://pubmed.ncbi.nlm.nih.gov/26639777/
Hou J, Weijian Y, Chen J. Current development and challenges of tetravalent live-attenuated dengue vaccines. *Front Immunol*. 2022;13:840104. doi:10.3389/fimmu.2022.840104	https://pubmed.ncbi.nlm.nih.gov/35281026/
Kallas EG, Precioso AR, Palacios R, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: A two-step, double-blind, randomised placebo-controlled phase 2 trial. *Lancet Infect Dis*. 2020;20(7):839-850. doi:10.1016/S1473-3099(20)30023-2	https://pubmed.ncbi.nlm.nih.gov/32220283/
Khertarpal N, Khanna I. Dengue fever: Causes, complications, and vaccine strategies. *J Immunol Res*. 2016;2016:6803098. doi:10.1155/2016/6803098	https://pubmed.ncbi.nlm.nih.gov/27525287/
Messina JP, Brady OJ, Golding N, et al. The current and future global distribution and population at risk of dengue. *Nat Microbiol*. 2019;4(9):1508-1515. doi:10.1038/s41564-019-0476-8	https://www.nature.com/articles/s41564-019-0476-8

Muller DA, Depelsenaire ACI, Young PR. Clinical and laboratory diagnosis of dengue virus infection. *J Infect Dis*. 2017;215(suppl 2):S89-S95. doi:10.1093/infdis/jiw649	https://pubmed.ncbi.nlm.nih.gov/28403441/
Obi JO, Gutiérrez-Barbosa, Chua JV, Deredge DJ. Current trends and limitations in dengue antiviral research. *Trop Med Infect Dis*. 2021;6(4):180. doi:10.3390/tropicalmed6040180	https://www.mdpi.com/2414-6366/6/4/180/htm
Osorio JE, Huang CYH, Kinney RM, Stinchcomb DT. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. *Vaccine*. 2011;29(42):7251-7260. doi:10.1016/j.vaccine.2011.07.020	https://pubmed.ncbi.nlm.nih.gov/21777638/
Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. *Expert Rev Vaccines*. 2016;15(4):497-508. doi:10.1586/14760584.2016.1128328	https://pubmed.ncbi.nlm.nih.gov/26635182/
Rivera L, Biswal S, Sáez-Llorens X, et al. Three year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003) [published online ahead of print, 2021 Oct 4]. *Clin Infect Dis*. 2021;ciab864. doi:10.1093/cid/ciab864	https://pubmed.ncbi.nlm.nih.gov/34606595/
Schaefer TJ, Panda PK, Wolford RW. Dengue fever. In: StatPearls [Internet]. StatPearls Publishing. Updated April 22, 2022.	https://www.ncbi.nlm.nih.gov/books/NBK430732/
Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. *N Engl J Med*. 2012;366(15):1423-1432. doi:10.1056/NEJMra1110265	https://www.nejm.org/doi/full/10.1056/nejmra1110265
Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. *N Engl J Med*. 2018;379(4):327-340. doi:10.1056/NEJMoa1800820	https://www.nejm.org/doi/full/10.1056/nejmoa1800820
Utarini A, Indriani C, Ahmad RA, et al. Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. *N Engl J Med*. 2021;384(23):2177-2186. doi:10.1056/NEJMoa2030243	https://www.nejm.org/doi/full/10.1056/nejmoa2030243
Valdés I, Lazo L, Hermida L, Guillén G, Gil L. Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus? *Front Immunol*. 2019;10:1956. doi:10.3389/fimmu.2019.01956	https://pubmed.ncbi.nlm.nih.gov/31507591/
Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. *N Engl J Med*. 2015;372(2):113-123. doi:10.1056/NEJMoa1411037	https://www.nejm.org/doi/full/10.1056/nejmoa1411037